This is a phase III randomized, multicenter study with two different arm:~experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin~comparator: standard surgery Adjuvant treatment after surgery is mandatory except for documented cases of non-eligibility.~Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the total resection of tumour will be reached and will use a stratification procedure based on center~The HIPEC CO2 regimen will be as reported below:~mitomycin: (total dose of 35 mg/mq, physiologic solution 0.9%) administrated 50% at time 0 from start of HIPEC CO2 treatment (17.5 mg/mq), 25% (8.8 mg/mq) after 30 minutes and the last dose 25% after 60 minutes. Recommended temperature for HIPEC treatment is 41-42 °C for 90 minutes.~Adjuvant treatment consists of a 6 months chemotherapy after surgery. It is possible to choose between Oxaliplatin, Capecitabine (XELOX) or Oxaliplatin, Fluorouracil, Leucovorin (FOLFOX-4) Patients affected by CRC at high risk of developing peritoneal carcinomatosis will be randomized in the study.
This is a phase III randomized, multicenter study with two different arm:~experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin~comparator: standard surgery Adjuvant treatment after surgery is mandatory except for documented cases of non-eligibility.~Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the total resection of tumour will be reached and will use a stratification procedure based on center